Sodium Bicarbonate Plus N-Acetylcysteine Prophylaxis A Meta-Analysis

The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, New Hampshire, USA.
JACC. Cardiovascular Interventions (Impact Factor: 7.35). 11/2009; 2(11):1116-24. DOI: 10.1016/j.jcin.2009.07.015
Source: PubMed


We sought to conduct a meta-analysis to compare N-acetylcysteine (NAC) in combination with sodium bicarbonate (NaHCO(3)) for the prevention of contrast-induced acute kidney injury (AKI).
Contrast-induced AKI is a serious consequence of cardiac catheterizations and percutaneous coronary interventions (PCI). Despite recent supporting evidence for combination therapy, not enough has been done to prevent the occurrence of contrast-induced AKI prophylactically.
Published randomized controlled trial data were collected from OVID/PubMed, Web of Science, and conference abstracts. The outcome of interest was contrast-induced AKI, defined as a >or=25% or >or=0.5 mg/dl increase in serum creatinine from baseline. Secondary outcome was renal failure requiring dialysis.
Ten randomized controlled trials met our criteria. Combination treatment of NAC with intravenous NaHCO(3) reduced contrast-induced AKI by 35% (relative risk: 0.65; 95% confidence interval: 0.40 to 1.05). However, the combination of N-acetylcysteine plus NaHCO(3) did not significantly reduce renal failure requiring dialysis (relative risk: 0.47; 95% confidence interval: 0.16 to 1.41).
Combination prophylaxis with NAC and NaHCO(3) substantially reduced the occurrence of contrast-induced AKI overall but not dialysis-dependent renal failure. Combination prophylaxis should be incorporated for all high-risk patients (emergent cases or patients with chronic kidney disease) and should be strongly considered for all interventional radio-contrast procedures.

  • Source
    • "Patients with previously known or suspected renal function impairment underwent a CT scan without contrast enhancement. Each patient received intravenous N-acetylcysteine and sodium bicarbonate to reduce contrast-induced nephropathy (8). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The aim of this study was to describe our early experience in the treatment of ruptured abdominal aortic aneurysms with bifurcated endografts. We report on our initial twelve-month experience using this approach. Methods: Clinical data on patients with ruptured abdominal aortic aneurysms treated at a single tertiary center in Brazil were prospectively recorded. The eligibility for endovascular treatment was evaluated by computed tomography scanning and anatomical features were determined based on the method of treatment. Results: From February 2012 to January 2013 (12 months), 28 consecutive patients (mean age 67.2 years, range 45-85 years) underwent treatment for ruptured abdominal aortic aneurysms at our hospital. Eighteen patients (64.3%) were suitable for and underwent endovascular treatment with bifurcated endografts (16 patients) or aortouniiliac endografts (two patients). Ten patients who were considered unsuitable for endograft repair underwent open repair. Seven patients were classified as hemodynamically unstable (Endovascular, 5; Open, 2), and 21 were classified as stable (Endovascular, 13; Open, 8). The overall 30-day mortality rate associated with endovascular treatment was 27.8% (stable, 18.7%; unstable, 40%) and the rate associated with open repair was 50% (stable, 37.5%; unstable, 100%). Conclusions: In this study, the suitability of patients for endovascular repair of ruptured abdominal aortic aneurysms was high and the overall results of endovascular treatment remain encouraging. Indeed, bifurcated endografts are a feasible option for treating anatomically eligible ruptured abdominal aortic aneurysms.
    Clinics (São Paulo, Brazil) 06/2014; 69(6):420-425. · 1.19 Impact Factor
  • Source
    • "The only preventive maneuvers generally accepted to have a limited but consistent efficacy are patient hydration with saline or bicarbonate solutions and the use of low-osmolality ICMs, which are supported by recent meta-analysis (Trivedi et al., 2010). Combination of NAC with intravenous bicarbonate reduced contrast-induced AKI by 35%, but not the number of cases requiring dialysis (Brown et al., 2009). Thus, at present, there are no highly effective methods to significantly reduce the incidence of CIN. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although generally reversible, contrast media toxicity often induces contrast-induced nephropathy (CIN), which is associated to longer hospitalization time, the need of dialysis, and higher incidence of later cardiovascular events and higher mortality. Preventive co-treatments have been assayed at the preclinical and clinical levels, but recent meta-analysis have not demonstrated a beneficial effect, which supports the search for new nephroprotective strategies. We have assessed if the administration of cardiotrophin-1 (CT-1), an endogenous cytokine with protective properties on the heart and liver, might mitigate CIN in rats. We have developed a model of CIN induced by the administration of the contrast medium gastrographin i.v. (3.7 mg/kg). in rats sensitized by previous administration of sub-nephrotoxic doses of gentamicin (50 mg/kg/day, i.p.) for 6 days. The severity of CIN was assessed by measurement of renal function, renal histological damage, urinary excretion of markers of tubular damage including NAG, KIM-1 and PAI-1, lipid peroxidation and renal apoptosis. Treatment with cardiotrophin-1 almost completely prevented the renal tissue damage as evidenced by almost total prevention of tubular desepithelization and tubular obstruction, reduced caspase activation and cell proliferation. Besides, CT-1 also prevented the increment in renal tissue levels of renal tissue injury markers NAG, KIM-1 and NGAL. Oxidative stress, a hallmark of contrast-induced nephropathy, was also prevented by CT-1. Administration of CT-1 also prevented the derangement in kidney function induced by CIN. Renal hemodynamics, also impaired by the contrast medium, were normal in rats co-treated with CT-1. Cardiotrophin-1 administration significantly prevents the alterations in renal function and structure observed in a rat model of CIN.
    Toxicological Sciences 01/2013; 132(2). DOI:10.1093/toxsci/kft007 · 3.85 Impact Factor
  • Source

    JACC. Cardiovascular Interventions 11/2009; 2(11):1125-7. DOI:10.1016/j.jcin.2009.08.019 · 7.35 Impact Factor
Show more